Floatz logo

Semaglutide

Chronic Kidney Disease

Institute of Liver and Biliary Sciences, Indiaprotein_peptidePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Chronic Kidney Disease cohort.

Asset / SponsorPhaseRating
SODIUM FERRIC GLUCONATE
Watson Pharmaceuticals
Phase 4BBB
IRON(II) SULPHATE (1:1), HEPTAHYDRATE
Watson Pharmaceuticals
Phase 4BBB
Plavix
Hospital Alemão Oswaldo Cruz
Phase 4BB
Acetylsalicylic Acid
Hospital Alemão Oswaldo Cruz
Phase 4BB
Retatrutide
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
81 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →